Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XBI-302 + nivolumab
- Development stage
- Unknown
- Lead developer
- Shenzhen Xbiome Biotechnology
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
XBI-302 + nivolumab is an investigational combination therapy consisting of orally administered fecal microbiota transplantation (FMT) capsules (XBI-302) and the immune checkpoint inhibitor monoclonal antibody, nivolumab. The combination is being studied primarily for its potential to overcome resistance to anti-PD-(L)1 therapies in cancer, particularly in patients with refractory or resistant solid tumors such as gastric cancer. XBI-302 is a gut microbial capsule developed by Shenzhen Xbiome Biotechnology and functions as a microbiome modulator, aiming to restore or alter the gut microbial composition to enhance immune responses. Nivolumab is a programmed death 1 (PD‑1) receptor-blocking antibody that enhances T-cell mediated antitumor activity by inhibiting PD‑1-mediated immune suppression. The rationale for combining these agents lies in evidence that modulation of the gut microbiota can improve response rates and efficacy of immunotherapies like anti-PD‑1 antibodies.
- Other names
- XBI-302 + nivolumabFMT capsules XBI-302 combined with nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on XBI-302 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XBI-302 + nivolumab.